BioMarin Pharmaceuticals (NASDAQ:BMRN) may be a potential activist investor target after 13-F filings from some prime brokers.
Barclays added over 2 million BioMarin (BMRN) shares in Q2 and had a 1.2% as of the end of June, according to a 13-filing. The Barclays disclosure came after UBS added 2.7 million shares of BMRN in Q1, Gordon Haskett's Don Bilson highlighted in a note earlier on Monday. UBS owned 4.26 million shares of BMRN as of June 30.
The additions from Barclays and UBS are noteworthy because prime brokerage sometimes acts as counterparties for activist swap positions.
Gordon Haskett's Bilson also highlighted BioMarin (BMRN) in early June after Bristol Myers (BMY) agreed to buy Turning Point Therapeutics (TPTX) for $4 billion in cash. The connection between TPTX and BMRN is that Mark Alles is the chairman of TPTX and Alles once ran Celgene, which was also acquired by Bristol Myers. In addition, Alles just took a board seat at BioMarin in December.
Also recall March 2021, BioMarin (BMRN) gained after some speculation from Betaville on potential takeover interest.